Immunobiology of inhibitor development in hemophilia A

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 1, 2003, Pages 61-68

  Fijnvandraat, Karin ^b   Bril, Wendy S ^a   Voorberg, Jan ^a  

^a CENTRAL LABORATORY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Factor VIII; Hemophilia; Inhibitors

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8A;

ANTIBODY PRODUCTION; ANTIGEN BINDING; B LYMPHOCYTE; CELLULAR IMMUNITY; EPITOPE MAPPING; HEMOPHILIA A; HUMAN; IMMUNE SYSTEM; IMMUNOBIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE;

EID: 0037325387     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37940     Document Type: Review

References (52)

1. Hoyer LW. Hemophilia. N Engl J Med 1994;330:38-47
2. Mannucci PM, Tuddenham EGD. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001;344:1773-1779
3. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995;270:14505-14509
4. 2 domain of human factor VIII. Blood 1998;92:3701-3709
5. Fijnvandraat K, Celie PHN, Turenhout EAM, et al. A human allo-antibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998;91:2347-2352
6. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998;92:136-142
7. Fay PL, Scandella D. Human inhibitors specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999;274:29826-29830
8. Arai M, Hoyer LW, Scandella D. Molecular basis of factor VIII inhibition by human antibodies - antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipids. J Clin Invest 1989;83:1978-1984
9. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999;5:1044-1047
10. Algiman M, Dietrich G, Nydegger UE, et al. Natural antibodies to factor VIII (antihemophilic factor) in healthy individuals. Proc Nat Acad Sci USA 1992;89:3795-3799
11. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-factor VIII idiotypic antibodies. J Clin Invest 1994;94:1496-1505
12. Moreau A, Lacroix-Desmazes S, Stieltjes N, et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000;95:3435-3441
13. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with an inhibitor. Blood 1998;92:496-506
14. Spiegel PC, Jacquemin M, Saint-Remy JMR, Stoddard BL, Pratt K. Structure of a factor VIII C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody on the surface of factor VIII. Blood 2001;98:13-19
15. Barrow RT, Healey JF, Jacquemin M, Saint-Remy JMR, Lollar P. Antigenicity of putative phospholipid membrane binding residues in factor VIII. Blood 2001;97:169-174
16. Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood 2000;95:156-163
17. Santagostino E, Gringeri A, Tagliavacca L, et al. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995;74:619-621
18. Peerlinck K, Jacquemin M, Arnout J, et al. Anti-factor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999;93:2267-2273
19. 593→Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997;89:4371-4377
20. van den Brink EN, Turenhout EAM, Davies J, et al. Human antibodies with spedficity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood 2000;95:558-563
21. van den Brink EN, Turenhout EAM, Bank CMC, et al. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood 2000;96:540-545
22. van den Brink EN, Turenhout EAM, Bovenschen N, et al. Multiple VH genes are used to assemble human antibodies directed towards the A3-C1 domains of factor VIII. Blood 2001;97:966-972
23. Voorberg J, van den Brink EN. Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII. Semin Thromb Hemost 2000;26:143-150
24. van den Brink EN, Bril WS, Turenhout EA, et al. Two classes of germline genes both derived from the V(H) 1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood 2002;99:2828-2834
25. Barrow RT, Healey JF, Gailiani D, Scandella D, Lollar P. Reduction of the antigenicity, of factor VIII towards complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000;95:564-568
26. Nogami K, Shima M, Giddings JC, et al. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis. Blood 2001;97:669-677
27. McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIII:C inhibltors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988;71:344-348
28. Schwaab R, Brackmann HH, Meyer C, et al. Mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-1406
29. Fakharzadeh S, Kazazian HH. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 2000;26:167-171
30. Goodeve A, Williams I, Bray GL, et al. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Thromb Haemost 200;83:844-848
31. Singer ST, Addieggo JE Jr, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996;76:17-22
32. Reding MT, Wu H, Krampf M, et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000;84:643-652
33. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995;10:119-121
34. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996;88:3446-3450
35. Sarkar R, Gao G, Chirmule N, et al. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 2000;11:881-894
36. Qian J, Borovok M, Bi L, Kazazian HH, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999;81:240-244
37. Reipert BM, Ahmad RU, Turecek PL, et al. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000;84:826-832
38. Hausl C, Maier E, Schwarz HP, et al. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002;87:840-845
39. Wu H, Reding M, Qian J, et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001;85:125-133
40. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001;97:2750-2757
41. Sasgary M, Ahmad RU, Schwarz HP, Turecek P, Reipert BM. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002;87:266-272
42. Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-223
43. Coyle AJ, Gutierrez-Romas J-C. The expanding B7 super-family: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-209
44. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994;83:3815-3825
45. Qian J, Collins M, Sharpe A, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000;95:1324-1329
46. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686-693
47. Qian J, Burkly LC, Smith EP, et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000;30:2548-2554
48. Reipert BM, Sasgary M, Ahmad RU, et al. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2002;86:1345-1352
49. Ewenstein BM, Hoots WK, Lusher JM, et al. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000;85:35-39
50. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114 (Letter)
51. Brackmann HH, Gormsen J. Massive factor VIII infusion in haemophiliacs with factor VIII inhibitor, high responder. Lancet 1977;8044:933 (Letter)
52. Mauser-Bunschoten EP, Hieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86:983-988